ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Oct 13, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ATLCAR.CD30.CCR4 cells for patients with Hodgkin Lymphoma, particularly those whose disease has come back or has not responded to previous treatments. Hodgkin Lymphoma is a type of cancer that affects the lymphatic system, and while there have been improvements in treatment, some patients still face serious health challenges. The goal of this trial is to see how well the new therapy is tolerated and to find the best dose to use in future studies.

To be eligible to participate, individuals must be at least 18 years old and have a diagnosis of Classical Hodgkin Lymphoma. They should also be in good overall health, as indicated by a score that measures their ability to perform daily activities. Participants will receive the new treatment after a preparation process and will be monitored for up to 15 years to understand its effects. During this time, they may also receive standard treatments to help manage their condition. This trial is currently recruiting participants and aims to help improve outcomes for those affected by this type of cancer.

Gender

ALL

Eligibility criteria

• • During the period of cell procurement and lymphodepletion, subjects will be eligible to receive standard-of-care therapy e.g., chemotherapy or radiation therapy to stabilize their disease if the treating physician feels it is in the subject's best interests. Eligibility must be maintained up until the subject is procured, receives lymphodepletion, or receives treatment for the subject to be considered eligible to proceed with the specific phase of the study.
• Inclusion Criteria:
• • Unless otherwise noted, subjects must meet all of the following criteria to participate in all phases of the study. As these criteria are unchanging they will be evaluated at the time of initial enrollment and not continuously throughout the study.
• • 1. Written informed consent and HIPAA authorization for release of personal health information explained to, understood by, and signed by the subject or legally authorized representative.
• • 2. Age ≥ 18 years at the time of consent.
• • 3. Karnofsky score of \> 60%
• • 4. The subject must have a diagnosis of Classical Hodgkin Lymphoma according to World Health Organization criteria.
• Exclusion Criteria:
• • 1. Subjects had major surgery within 28 days.
• • 2. Subject received investigational agents or tumor vaccines within 3 weeks.
• • 3. Subject received chemotherapy or radiation therapy within the previous 3 weeks.